Loading...
Loading...
SNSE| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.5M |
| Gross Profit | -0.5M |
| Operating Expense | 11.0M |
| Operating I/L | -11.0M |
| Other Income/Expense | 0.8M |
| Interest Income | 1.0M |
| Pretax | -10.2M |
| Income Tax Expense | -1.2M |
| Net Income/Loss | -8.9M |
Sensei Biotherapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of immunotherapies for cancer treatment. The company's proprietary ImmunoPhage platform utilizes bacteriophage to trigger a targeted innate and adaptive immune response, while its Tumor Microenvironment Activated Biologics platform aims to unleash the anti-tumor potential of T-cells. Sensei Biotherapeutics also develops monoclonal antibodies, including SNS-101 for cancer treatment and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. Additionally, the company collaborates with The University of Washington to research and develop a vaccine for Merkel cell carcinoma.
